{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:28:23Z","timestamp":1788449303451,"version":"build-2803163510"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study utilized FDA Adverse Event Reporting System (FAERS) data and network pharmacology methods to evaluate the risk of renal adverse events (AEs) associated with calcineurin inhibitors (CNIs), providing guidance for safe drug use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>By analyzing FAERS data from 2004 to 2024, we identified renal AEs associated with CNI therapy. We employed imbalance analysis (report odds ratio [ROR], proportion of reports ratio [PRR], MGPS, and Bayesian confidence propagation neural network [BCPNN]) to detect signals and explored drug-gene interaction networks to investigate potential mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Revealed significant associations between cyclosporine, tacrolimus, and voclosporin with renal injury, with voclosporin showing stronger correlations (ROR = 5.24, PRR = 4.85, EBGM05 = 4.85, IC025 = 2.28) but lower mortality rates. Network pharmacology analysis suggested that cyclosporine, tacrolimus, and everolimus may exert their toxic effects by acting on core genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The widespread use of CNIs raises concerns about their renal safety. This study provides new evidence from real-world data indicating differences in renal toxicity risk and mechanisms among calcineurin inhibitors (CNIs), underscoring the importance of pharmacovigilance strategies for patients with autoimmune diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1764130","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:51:04Z","timestamp":1776343864000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Kidney adverse events associated with calcineurin inhibitors: a real-world study based on the FAERS database and network pharmacology"],"prefix":"10.3389","volume":"13","author":[{"given":"YaoYun","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, The Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XinYu","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Dai","sequence":"additional","affiliation":[{"name":"Institute of Basic Medicine, North Sichuan Medical University, Institute of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical University","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Affiliated Hospital of North Sichuan Medical College","place":["Nanchong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"B1","article-title":"Calcineurin inhibitors","author":"Safarini","year":"2023","journal-title":"StatPearls"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e42858","DOI":"10.1097\/MD.0000000000042858","article-title":"Voclosporin: a comprehensive review of its role as a novel calcineurin inhibitor in the management of systemic lupus erythematosus","volume":"104","author":"Ashinze","year":"2025","journal-title":"Medicine."},{"key":"B3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s12035-025-05549-2","article-title":"Calcineurin inhibitors: current role, toxicity management, and future frontiers in immunosuppression","volume":"63","author":"Mistry","year":"2025","journal-title":"Mol Neurobiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/ki.1980.181","article-title":"Metabolism of drugs by the kidney","volume":"18","author":"Anders","year":"1980","journal-title":"Kidney Int."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2174\/1389200218666171108154419","article-title":"Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers and prevention strategies","author":"Wu","year":"2018","journal-title":"Curr Drug Metab."},{"key":"B7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/FTD.0000000000000589","article-title":"Biomarkers of drug-induced kidney toxicity","volume":"41","author":"Griffin","year":"2019","journal-title":"Ther Drug Monit."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1007\/s00204-019-02598-0","article-title":"Kidney-based in vitro models for drug-induced toxicity testing","volume":"93","author":"Faria","year":"2019","journal-title":"Arch Toxicol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","author":"Guo","year":"2022","journal-title":"Sci Rep."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2174\/0113894501290296240327081624","article-title":"Drug repurposing using FDA adverse event reporting system (FAERS) database","author":"Morris","year":"2024","journal-title":"Curr Drug Targets."},{"key":"B11","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","article-title":"Limitations and strengths of spontaneous reports data","volume":"20","author":"Goldman","year":"1998","journal-title":"Clin Ther."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae272","article-title":"Network pharmacology as a platform for drug discovery for hypertrophic scars","author":"Wang","year":"2024","journal-title":"Br J Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"et al. OpenVigil FDA \u2013 inspection of US american adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS ONE."},{"key":"B14","unstructured":""},{"key":"B15","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"D447","DOI":"10.1093\/nar\/gku1003","article-title":"STRING v10: protein\u2013protein interaction networks, integrated over the tree of life","volume":"43","author":"Szklarczyk","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B18","article-title":"Calcineurin Inhibitors","author":"Safarini","year":"2025","journal-title":"In: StatPearls"},{"key":"B19","doi-asserted-by":"publisher","first-page":"s82","DOI":"10.1590\/1806-9282.66.s1.82","article-title":"Drug-induced nephrotoxicity","volume":"66","author":"Sales","year":"2020","journal-title":"Rev Assoc M\u00e9dica Bras."},{"key":"B20","doi-asserted-by":"publisher","first-page":"SS11","DOI":"10.1097\/00007890-200006271-00003","article-title":"Nephrotoxicity","volume":"69","author":"Davies","year":"2000","journal-title":"Transplantation."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh739","article-title":"Efficacy and safety of tacrolimus compared with cyclosporin a microemulsion in renal transplantation: 2 year follow-up results","author":"Kr\u00e4mer","year":"2005","journal-title":"Nephrol Dial Transplant."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/art.43209","article-title":"Effect of long-term voclosporin treatment on renal histology in patients with active lupus nephritis with repeat renal biopsies","volume":"77","author":"Rovin","year":"2025","journal-title":"Arthritis Rheumatol Hoboken Nj."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2006.12.004","article-title":"Gender as risk factor for autoimmune diseases","volume":"28","author":"Gleicher","year":"2007","journal-title":"J Autoimmun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s10528-017-9795-8","article-title":"Sex differences in the blood concentration of tacrolimus in systemic lupus erythematosus and rheumatoid arthritis patients with CYP3A5*3\/*3","volume":"55","author":"Ito","year":"2017","journal-title":"Biochem Genet."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11040252","article-title":"Effects of CYP3A5 polymorphism on rapid progression of chronic kidney disease: a prospective, multicentre study","author":"Lee","year":"2021","journal-title":"J Pers Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s40266-017-0484-4","article-title":"Drug-induced kidney injury in the elderly","volume":"34","author":"Khan","year":"2017","journal-title":"Drugs Aging."},{"key":"B27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14740338.2017.1323867","article-title":"Hansen RA. Empirical estimation of under-reporting in the US food and drug administration adverse event reporting system (FAERS)","volume":"16","author":"Alatawi","year":"2017","journal-title":"Expert Opin Drug Saf."},{"key":"B28","doi-asserted-by":"publisher","first-page":"230386","DOI":"10.1155\/2012\/230386","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J Transplant."},{"key":"B29","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.1016\/j.transproceed.2004.01.021","article-title":"Cyclosporine nephrotoxicity","volume":"36","author":"Busauschina","year":"2004","journal-title":"Transplant Proc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"101589","DOI":"10.1016\/j.jbc.2022.101589","article-title":"Immunosuppressive calcineurin inhibitor cyclosporine A induces proapoptotic endoplasmic reticulum stress in renal tubular cells","volume":"298","author":"Yilmaz","year":"2022","journal-title":"J Biol Chem."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198409133111103","article-title":"Cyclosporine-associated chronic nephropathy","author":"Myers","year":"1984","journal-title":"N Engl J Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/01.tp.0000173594.69089.a0","article-title":"Cyclosporine-induced renal injury induces toll-like receptor and maturation of dendritic cells","volume":"80","author":"Lim SW Li","year":"2005","journal-title":"Transplantation."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1506760","DOI":"10.3389\/fphar.2025.1506760","article-title":"Post-marketing safety surveillance of voclosporin: an observational, pharmacovigilance study leveraging faers database study on the safety of voclosporin","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.3390\/jcm10214832","article-title":"Old and New Calcineurin inhibitors in lupus nephritis","volume":"10","author":"Ponticelli","year":"2021","journal-title":"J Clin Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1124\/jpet.341.903010","volume":"389","author":"Dang","year":"2024","journal-title":"J Pharmacol Exp Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40262-023-01246-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of voclosporin","volume":"62","author":"Abdel-Kahaar","year":"2023","journal-title":"Clin Pharmacokinet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/CPAA.S255789","article-title":"Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies","volume":"12","author":"Li","year":"2020","journal-title":"Clin Pharmacol Adv Appl."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3904\/kjim.2020.323","article-title":"Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J Intern Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00228-017-2204-8","article-title":"High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury","volume":"73","author":"Sikma","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00125480-199707000-00032","article-title":"Tacrolimus (FK506)-associated renal pathology","volume":"4","author":"Randhawa","year":"1997","journal-title":"Adv Anat Pathol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/00007890-200203150-00021","article-title":"A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years1","volume":"73","author":"Vincenti","year":"2002","journal-title":"Transplantation."},{"key":"B42","unstructured":""},{"key":"B43","unstructured":"Calcineurin inhibitors"},{"key":"B44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.kint.2023.09.001","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the management of lupus nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e18636","DOI":"10.7717\/peerj.18636","article-title":"CYP3A4 and CYP3A5: The crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1334440","article-title":"CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation","author":"Seligson","year":"2024","journal-title":"Front Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/PGPM.S131390","article-title":"Association of the PPP3CA c","volume":"10","author":"Salgado","year":"2017","journal-title":"Pharmacogenomics Pers Med."},{"key":"B48","unstructured":""},{"key":"B49","first-page":"14","article-title":"Microrna-30s reverse AngII-induced podocyte injury","volume":"26","author":"Zhao","year":"2017","journal-title":"Chin J Nephrol Dial Transplant."},{"key":"B50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-020-05195-0","article-title":"Associations of FKBP4 and FKBP5 gene polymorphisms with disease susceptibility, glucocorticoid efficacy, anxiety, depression, and health-related quality of life in systemic lupus erythematosus patients","volume":"40","author":"Lou","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.21037\/atm-20-1757","article-title":"Differential expression of genes related to calcineurin and mTOR signaling and regulatory miRNAs in peripheral blood from kidney recipients under tacrolimus-based therapy","volume":"8","author":"Bonezi","year":"2020","journal-title":"Ann Transl Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00018-023-04958-7","article-title":"FKBP5 deficiency attenuates calcium oxalate kidney stone formation by suppressing cell\u2013 crystal adhesion, apoptosis and macrophage M1 polarization via inhibition of NF-\u03baB signaling","volume":"80","author":"Song","year":"2023","journal-title":"Cell Mol Life Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/eji.201847699","article-title":"FKBP51 modulates steroid sensitivity and NF\u03baB signalling: a novel anti-inflammatory drug target","volume":"48","author":"K\u00e4stle","year":"2018","journal-title":"Eur J Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5125\/jkaoms.2023.49.6.311","article-title":"Review of two immunosuppressants: tacrolimus and cyclosporine","volume":"49","author":"Lee","year":"2023","journal-title":"J Korean Assoc Oral Maxillofac Surg."},{"key":"B55","doi-asserted-by":"publisher","first-page":"F284","DOI":"10.1152\/ajprenal.00081.2025","article-title":"Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors","volume":"329","author":"Uyl","year":"2025","journal-title":"Am J Physiol Renal Physiol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-8206.2002.00114.x","article-title":"In vitro effects of tacrolimus on human cytochrome P450","author":"Lecointre","year":"2002","journal-title":"Fundam Clin Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"107420","DOI":"10.1016\/j.intimp.2021.107420","article-title":"Insights into the modulatory role of cyclosporine A and its research advances in acute inflammation","volume":"93","author":"Gui","year":"2021","journal-title":"Int Immunopharmacol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1764130\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:51:07Z","timestamp":1776343867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1764130\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":57,"alternative-id":["10.3389\/fmed.2026.1764130"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1764130","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1764130"}}